Acorda Therapeutics, Inc.
ACOR
Classifica tra le azioni
#39155
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Prezzo delle azioni
$0.879
Ultima sincronizzazione: 2024-05-07
Capitalizzazione di mercato
$582.38K
Variazione (1 giorno)
9.88%
Variazione (1 anno)
8,690.00%
Paese
US
Scambia Acorda Therapeutics, Inc. (ACOR)
Categoria
Healthcare
EPS per Acorda Therapeutics, Inc. (ACOR)
EPS al March 2024 TTM: $-262.58
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Acorda Therapeutics, Inc., l’EPS attuale della società (TTM) è $-262.58. Alla fine del 2022, la società aveva un EPS di $-66.90 un aumento rispetto a rispetto a quello del 2021, che era di $-195.75.
Storico EPS per Acorda Therapeutics, Inc. da 2016 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-262.58 | 28.97% |
| 2023 | $-203.59 | 204.32% |
| 2022 | $-66.90 | -65.82% |
| 2021 | $-195.75 | -20.56% |
| 2020 | $-246.40 | -64.26% |
| 2019 | $-689.42 | -901.84% |
| 2018 | $85.98 | -114.76% |
| 2017 | $-582.69 | 534.81% |
| 2016 | $-91.79 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -100.21% |
IN
|
